By Bob DeMarco
A daily dosage of insulin nasal spray has shown to have a positive impact and improve memory in adults with a mild memory impairment or Alzheimer’s disease(AD).
+Alzheimer's Reading Room
I recently received an email from Lynda Everman reminding me of this ongoing clinical trial research investigation on Alzheimer's disease and forgetfulness.
The purpose of the SNIFF study is to find out whether a type of insulin, when administered as a nasal spray, improves memory in adults with a mild memory impairment or Alzheimer’s disease (AD).
This study is currently in urgent need of new participants in order to insure that the research moves forward.
The rationale behind the study is growing evidence that insulin carries out multiple functions in the brain and that poor regulation of insulin may contribute to the development of AD. Insulin resistance, reduced cerebrospinal fluid insulin levels, and reduced brain insulin signals have been found in AD patients, suggesting that a therapy aimed at correcting these deficiencies may be beneficial.
|Subscribe to the Alzheimer's Reading Room|
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages.
The emotional and financial burden of AD to patients, family members, and society is enormous, and is predicted to grow exponentially as the median population age increases.
Current FDA-approved therapies are modestly effective at best. This study will examine a novel therapeutic approach using intranasal insulin (INI) that has shown promise in short-term clinical trials. If successful, information gained from the study has the potential to move INI forward rapidly as a therapy for AD. The study will also provide evidence for the mechanisms through which INI may produce benefits by examining key cerebral spinal fluid (CSF) biomarkers and hippocampal/entorhinal atrophy.
This study will examine the effects of intranasally-administered insulin on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid (CSF) biomarkers in amnestic mild cognitive impairment (aMCI) or mild AD. It is hypothesized that after 12 months of treatment with INI compared to placebo, subjects will improve performance on a global measure of cognition, on a memory composite and on daily function.
To learn everything you need to know about this study including" purpose, eligibility criteria, and contact information go to this page on ClinicalTrials.gov.
To get a list of the 30 locations currently available for this study go down to the bottom on this webpage.
The necessary contact information is included.
I would encourage everyone to consider participation in this clinical trial. If successful it could provide an effective treatment for Alzheimer's disease, and short term memory loss.
- Test Your Memory for Alzheimer's Disease (5 Best Self Tests)
- What’s the Difference Between Alzheimer’s and Dementia
- What Was the First Sign of Alzheimer's Disease in Your Case?
- Communicating in Alzheimer's World
- Rewiring My Brain and Stepping into Alzheimer's World
- Learning How to Communicate with Someone Living with Dementia
- Alzheimer's Communication Tip, No More Blah Blah Blah
The Alzheimer's Reading Room (ARR) offers a searchable Knowledge Base that contains over 4,800 articles Those article and all of our intellectual capital are offered free of charge and are available to the entire Alzheimer's community via the ARR website.